Literature DB >> 6385635

The effect of acebutolol on plasma lipids, blood glucose and serum insulin levels.

A Lehtonen.   

Abstract

The effect on plasma lipids of acebutolol given orally over a 6-month period to 18 patients with essential hypertension was studied. There were no significant changes in the concentrations of plasma total cholesterol, LDL cholesterol, VLDL cholesterol and triglycerides during treatment. The level of HDL cholesterol decreased slightly but not significantly during treatment. Plasma free fatty acids decreased significantly (p less than 0.05) during treatment with acebutolol. During an oral glucose tolerance test, blood glucose values were elevated after acebutolol therapy at 60 (p less than 0.05) and 120 min (p less than 0.05). No impairment of insulin release was observed after acebutolol therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6385635     DOI: 10.1111/j.0954-6820.1984.tb03771.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  5 in total

Review 1.  Effects of acebutolol on the serum lipid profile.

Authors:  A Clucas; N Miller
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs.

Authors:  R P Ames
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

3.  Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.

Authors:  T Pollare; H Lithell; I Selinus; C Berne
Journal:  BMJ       Date:  1989-04-29

Review 4.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

5.  Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients.

Authors:  A Lehtonen
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.